Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Beta Bionics, Inc.NASDAQ: BBNX
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 59.5%
Gross margin was 59.5% in Q1 FY2026, up 8.6 pp from a year earlier. On a trailing-twelve-month basis it was 57.2%, up 3.2 pp year over year. Over 3 fiscal years it narrowed by 44.6 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 55.4%
- Year-over-year change
- +0.3pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 55.4% | +0.3pp |
| FY2024 | 2024-12-31 | 55.1% | +2.5pp |
| FY2023 | 2023-12-31 | 52.6% | -47.4pp |
| FY2022 | 2022-12-31 | 100.0% | — |
Gross Margin vs competitors
How BBNX compares with its peers on the latest reported figures
- BBNX's LTM Mar 2026 gross margin of 57.2% is the 5th highest of the 8 companies compared; the peer median is 62.5%.
- Its year-over-year change of +3.2 pp is the 3rd highest of 6, against a peer median of +1.3 pp.
- Over three fiscal years its change of -44.6 pp compares with a peer median of -2.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 80.6% | -3.3 pp | -2.9 pp | |
| LTM Mar 2026 | 76.0% | +1.3 pp | +40.1 pp | |
| LTM Jun 2026 | 71.1% | +0.3 pp | +9.9 pp | |
| LTM Jun 2026 | 62.5% | +3.7 pp | -4.6 pp | |
| LTM Mar 2026 | 57.2% | +3.2 pp | -44.6 pp | |
| LTM Mar 2026 | 54.9% | +8.4 pp | +0.8 pp | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | 53.8% | — | -4.1 pp |
| FY2025 | 0.7% | — | -99.4 pp | |
| Peer median (excluding BBNX) | 62.5% | +1.3 pp | -2.9 pp | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 179K | 12M | 65.12M | 100.25M |
| Cost of Revenue | 0 | 5.69M | 29.24M | 44.71M |
| Gross Profit | 179K | 6.31M | 35.89M | 55.54M |
| Gross Margin | 100.0% | 52.6% | 55.1% | 55.4% |
| Research & Development | 31.43M | 17.94M | 26.18M | 34.79M |
| Selling, General & Admin | 33.5M | 24.22M | 54.96M | 92.43M |
| Operating Expenses | 66.02M | 42.16M | 81.14M | 127.22M |
| Depreciation & Amortization | 1.35M | 1.23M | 1.15M | 2.88M |
| EBITDA | (63.4M) | (42.87M) | (53.61M) | (70.32M) |
| EBITDA Margin | -35418.4% | -357.4% | -82.3% | -70.1% |
| Operating Income | (65.84M) | (35.85M) | (45.25M) | (71.68M) |
| Operating Margin | -36784.4% | -298.9% | -69.5% | -71.5% |
| Interest Income | 196K | 1.78M | 3.91M | 10.93M |
| Interest Expense | 14K | 0 | 0 | 0 |
| Other Income / Expenses | 1.09M | (8.25M) | (9.51M) | (1.52M) |
| Income Before Tax | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Pre-Tax Margin | -36173.7% | -367.6% | -84.1% | -73.0% |
| Income Tax Expense | 0 | 0 | 0 | 1K |
| Net Income | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Net Margin | -36173.7% | -367.6% | -84.1% | -73.0% |
| EPS (Basic) | (12.96) | (8.31) | (8.60) | (1.81) |
| EPS (Diluted) | (12.96) | (8.31) | (8.60) | (1.81) |
| Weighted Avg Shares | 5M | 5.3M | 6.37M | 40.53M |
| Weighted Avg Shares (Diluted) | 5M | 5.3M | 6.37M | 40.53M |
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.